Luciano J Costa (@end_myeloma) ranks #6 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 28 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: SUCCESSOR-2, BMS-986453, EXCALIBER-RRMM. CMS Open Payments lists $90,871 in 2025 general payments.
At a Glance
- 5 posts naming a trial since ASH 2025
- 5 trials discussed by name
- Multiple Myeloma: US #6, Global #6 · 28 physicians engaged
- Leading physician voice: #2 of 3 physicians on BMS-986453
- Presented at ASH 2025, IMS 2026 in 2026
- CMS Open Payments lists $90,871 in 2025 general payments.
This Month
What Luciano J Costa has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
Who Amplifies Luciano J Costa
Physicians who reposted Luciano J Costa’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #6 | #6 | 71/100 | 28 | 59 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Luciano J Costa presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASH 2025 · Oral (abstract 94)Long-term PFS with cilta-cel in standard-risk RRMM (CARTITUDE-4)
- ASH 2025 · Oral (abstract 1037)Redefining functional high-risk MM with quadruplet therapy and ASCT (MASTER)Source: Multiple Myeloma Hub ↗
- IMS 2026 · Oral (abstract OA-49)MajesTEC-3 post hoc analysis: OS, progression and non-relapse mortality with Tec-Dara vs dara-based tripletsSource: @MM_Hub on X ↗
- IMS 2026 · PosterCB-011, an allogeneic anti-BCMA CAR-T with immune cloaking, in RRMM (PA-067, first author)
What Colleagues Are Saying About Luciano J Costa
2026 posts by fellow physicians that mention @end_myeloma, quoted word for word.
Just out in @NEJM Majestec-3 trial. Tec-Dara in relapsed myeloma. #ASH25 @End_myeloma @mvmateos Link: https://t.co/DnTeuBMsLU More in thread https://t.co/GrYwRuLUIL
My top 8 myeloma/amyloidosis #ASH25 abstracts @ASH_hematology #mmsm 🧵 1⃣CARTITUDE-4 longer follow up ~ 3yrs : (Abstract #297774 - @End_myeloma ) ➡️ In ITT population, pts with standard-risk cytogenetics had a 2.5 years PFS rate of 71% in the cilta-cel arm vs 43% in control
INCREDIBLE #ASH25 LBA by @mvmateos @End_myeloma et al. bsAbs stealing the show across #MMsm LoT! As we all admire MajesTEC-3 PFS HR, I'll add the key reason IMO this was possible: Q4W tec dosing & primary IVIG PPx. Fewer Gr3+ infxns ➡️ stay on bsAb/CD38 longer ➡️ victory 👏 https://t.co/9VGnKpamsu https://t.co/gQFFCenz5M
Ph3 RCT teclistamab + daratumumab vs investigator’s choice of dara-dex + either pomalidomide or bortezomib (DPd/DVd) in Pts w/RRMM: Results of MajesTEC-3 [Dec 9, 2025] @mvmateos et al. @End_myeloma #ASH25 LBA6 https://t.co/05T5SpqCpg #NCT05083169 #mmsm #IDonc PFS https://t.co/xPCzZ94ewH
What an honor to be part of the MM community as these changes happen. It is "not the end of the beginning, but the beginning of the end for myeloma." Rarely do you see such HR in MM. Congratulations to all investigators, J&J, @End_myeloma and @mvmateos for this study. #ASH25RF https://t.co/IPRVplUwgD
Looking forward to seeing the data on teclistamab and daratumumab in MajesTEC-3 presented at #ASH25 by @mvmateos @End_myeloma . The study population of 1-3 prior lines, prior PI and IMiD, and control arm of dara pom dex or dara Vel dex is similar to CARTITUDE-4 with cilta-cel
Trials Luciano J Costa Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| SUCCESSOR-2 | 2 | #10 of 15 | May 30, 2026 |
| BMS-986453 | 1 | #2 of 3 | Sep 27, 2026 |
| EXCALIBER-RRMM | 1 | #13 of 13 | Aug 17, 2026 |
| MajesTEC-9 | 1 | #15 of 16 | May 30, 2026 |
| CARTITUDE-4 | 1 | #8 of 9 | May 29, 2026 |
Luciano J Costa on SUCCESSOR-2
Why SUCCESSOR-2 is a valid, practice-informing trial and should support approval of Mezigdomide in combination with Carfilzomib and Dexamethasone. I hear some grievance about Kd as control, would argue they are ill informed. 1/x #mmsm
Cartitude 4, Tec-3, Tec-9, Tal-3, Tal-6, successor-2, MagnetisMM-5, MagnetisMM-32 are all valid practice-informing trial. Their controls were appropriate given the evidence at time of design and accrual. But they set a new benchmark against which future Rx must be compared.
Luciano J Costa on BMS-986453
The future is multi-targeted! BMS-986453 is a potential next best-in-class autologous CAR T-cell therapy in MM. @ONealCancerUAB @BMS_Myeloma_US https://t.co/jSho7Mk1RN
Luciano J Costa on EXCALIBER-RRMM
until we have a publication, the most we can learn about Iberdomide and Excaliber-RRMM is from the label. Not ideal, but better than press release😊 @rajshekharucms https://t.co/3Ndf0eaVxq
Luciano J Costa on MajesTEC-9
Incidentally, the exact same arguments can be made about Kd/PVd in control of MajesTEC-9. @JJ_IMMedAffairs https://t.co/syzVrdo1ZU
Luciano J Costa on CARTITUDE-4
Cartitude 4, Tec-3, Tec-9, Tal-3, Tal-6, successor-2, MagnetisMM-5, MagnetisMM-32 are all valid practice-informing trial. Their controls were appropriate given the evidence at time of design and accrual. But they set a new benchmark against which future Rx must be compared.
Luciano J Costa’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Implications are many: Off-the-shelf, highly active, outpatient-based, community-accessible, T-cell redirecting therapy. Steroid free with a convenient schedule. It will force us to reappraise options in 1-3 LOT. https://t.co/gnVq6bOcxN
Industry Payments
CMS Open Payments · 2025 general payments
$90,871 across 53 payments